Novartis' Setback: A $12 Billion Lesson That Doused the Industry in Cold Water
Hello everyone, I'm your financial journalist and friend, economist.
Recently, there's been a major incident in the pharmaceutical world, with the pharmaceutical giant Novartis at the center of it. In short, Novartis messed up three things in just one week, with the most devastating consequences coming from the failure of two of their key new drugs in the final phase of clinical trials (phase three). This has led to dissatisfaction among Novartis' major shareholders, who are demanding changes to the board of directors or stricter regulations, especially since one of these drugs cost Novartis a whopping $12 billion (about 85 billion RMB) in acquisition costs.
This incident isn't just about Novartis' stock price or reputation; it also affects the entire pharmaceutical industry's confidence in the promising field of "small nucleic acid drugs." Today, I'll break down what happened and what the implications are in simple terms.
---
Summary of the Key Points: What Happened to Novartis?
In one sentence: Novartis' stock price plummeted due to the failure of two key new drugs, sparking anger from major shareholders and raising doubts about the efficacy of small nucleic acid drugs in treating diseases.
Key Facts:
1. Double Blow:
- Pelacarsen (lipid-lowering drug): Developed in collaboration with Ionis, this drug was intended to reduce the level of "bad cholesterol" called Lp(a). Although it did lower Lp(a) levels, it failed to demonstrate a reduction in the risk of heart attacks.
- Del-desiran (muscle disease drug): Acquired from Avidity for $12 billion, this drug was designed to treat a rare muscle wasting condition. It also failed to meet expectations in phase three trials.
2. Severe Consequences:
- Novartis' stock price dropped by nearly 14% in a single day, the largest decline in recent years.
- This affected the stock prices of related companies, including Ionis, competitor Amgen, and Dyne, which also saw significant declines.
- Internal turmoil: Major shareholder Artisan Partners called for increased oversight of Novartis' acquisitions, suggesting that the management focuses too much on acquisitions without proper evaluation and that those who approved the failed deals should bear the consequences.
3. Industry Impact:
- These two drugs represented two of the most promising areas for small nucleic acid drugs: treating chronic cardiovascular diseases and delivering drugs to locations outside the liver.
- The failure has raised questions about whether small nucleic acid drugs are overhyped and whether they provide real therapeutic benefits rather than just lowering indicators.
---
In-depth Analysis: Why Did Novartis Fail?
1. **Misalignment in Technical Approaches: The Drugs Were Delivered to the Wrong Places**
This is the core technical issue. The failure wasn't due to the drugs not being developed or not being absorbed by the body, but rather because they were delivered to the wrong targets or not in sufficient amounts.
- Pelacarsen (ASO technology):
- Explanation: Lp(a) is considered "garbage" in the bloodstream. Novartis used ASO (antisense oligonucleotides) to cut the genes that produce this substance. However, it only reduced Lp(a) levels by about 80%, which experts believe needs to be reduced by 95% to effectively prevent heart attacks. It's like cleaning a room but only removing 80% of the dust, leaving the remaining 20% causing problems.
- Patient Selection: Novartis included patients with lower Lp(a) levels in the trials, diluting the results. In contrast, competitor Amgen targeted higher-risk patients and achieved a 95% reduction, possibly leading to better results.
- Del-desiran (AOC technology):
- Explanation: This is a more advanced technology using AOC (antibody-oligonucleotide conjugates) to deliver drugs directly to muscle cells. The problem was that the "delivery address" (TfR1 receptor) was present in multiple locations, leading to insufficient drug delivery. Additionally, the delivery mechanism was too strong, preventing the drug from releasing inside the cells.
- Experts suggest: Novartis might have chosen the wrong technical approach. For Lp(a), siRNA (another type of small nucleic acid) could have been more effective, and for muscle diseases, ASO might be more suitable for reaching the cell nucleus.
2. **Blunders in Business Strategy: The $12 Billion Acquisition**
If technical failures can be attributed to luck, then management decisions were clear mistakes.
- The High Cost of the Acquisition: Novartis' CEO spent $12 billion to acquire Avidity, the largest acquisition in the company's past decade. This investment included not only Del-desiran but also Avidity's delivery technology. Now that the core drug has failed, the expected annual revenue of $3 billion is gone, and the high cost means a long payback period, if ever possible.
- Shareholder Discontent: Major shareholder Artisan Partners is upset not because of the drug's failure (which is common in research and development), but because they question the lack of due diligence before the acquisition. They demand stricter oversight and accountability for decision-makers.
3. **Erosion of Industry Confidence: Are Small Nucleic Acid Drugs a Passing Fancy?**
This incident has shaken the industry because it affects two of the hottest areas in pharmaceutical research:
- Chronic Cardiovascular Diseases: Small nucleic acid drugs promise long-lasting effects, which could revolutionize treatments for conditions like hypertension and high cholesterol.
- Extrahepatic Delivery: These drugs aim to deliver drugs to locations outside the liver. Novartis' failures have raised doubts about whether they can truly be effective for these conditions.
4. Why Did Novartis Make These Mistakes?
- Technical Missteps: The failure was due to the drugs not being delivered to the correct targets or in sufficient amounts.
- Business Logic: The $12 billion acquisition was based on unproven technology, which turned out to be a costly mistake. The board may need to reconsider its approach to acquisitions and evaluate the risks more carefully.
5. The Future of Small Nucleic Acid Drugs**
Novartis' setback doesn't mean the end of small nucleic acid drugs. Instead, it marks a shift towards more cautious and effective research:
- Evolution of the Field:
- The focus has shifted from proving the feasibility of these drugs to refining their delivery methods and identifying the most effective targets and patient populations.
- New players like Dyne have opportunities to innovate in delivery technologies and target selection.
- Implications for Chinese Companies: Small nucleic acid drugs could become a competitive area for Chinese pharmaceutical companies, building on existing successes in related technologies.
- Novartis' failure provides valuable lessons for others, emphasizing the importance of careful research, targeted approaches, and effective delivery mechanisms.
---
Conclusion
Novartis' experience serves as a stark reminder that new drug development is not about luck but requires precise planning and effective execution. The failure of small nucleic acid drugs highlights the challenges in this field and the need for careful consideration of technical approaches, patient selection, and therapeutic effects. It also highlights the rapid changes in the pharmaceutical industry, where companies must adapt to evolving regulatory environments and technological advancements.